An international research consortium recently published the findings of a large-scale, phase III, double-blind trial. The study assessed a novel oral small-molecule immunosuppressant against a placebo for maintaining clinical remission in adults with severe ulcerative colitis.
A total of participants were enrolled and randomly assigned in a ratio to receive either the novel drug or the placebo. All participants were followed for a -week maintenance phase. By the end of the study, clinical disease relapse occurred in patients in the placebo group and patients in the intervention group.
Based on these trial results, what is the number needed to treat (NNT) to prevent one disease relapse over the -week period? (Calculate the exact value and apply the standard biostatistical rounding rule for NNT).
Cevap: 25 patients